Pasquini, M. C. et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 4, 5414–5424 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boardman, A. P. & Salles, G. CAR T-cell therapy in large B cell lymphoma. Hematol. Oncol. 41, 112–118 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Gardner, R. A. et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129, 3322–3331 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–448 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haghikia, A. et al. Anti-CD19 CAR T cells for refractory myasthenia gravis. Lancet Neurol. 22, 1104–1105 (2023).

Article  CAS  PubMed  Google Scholar 

Auth, J. et al. CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series. Lancet Rheumatol. 7, e83–e93 (2024).

Article  PubMed  Google Scholar 

Qin, C. et al. Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy. Proc. Natl Acad. Sci. USA 121, e2315990121 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lodka, D. et al. CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury. Ann. Rheum. Dis. 83, 499–507 (2024).

Article  CAS  PubMed  Google Scholar 

Lee, J. et al. Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. J. Clin. Invest. 130, 6317–6324 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sadun, R. E. & Foster, M. H. Deja vu but new: using T cells to deplete B cells to treat lupus. Am. J. Kidney Dis. 74, 708–710 (2019).

Article  PubMed  Google Scholar 

Kansal, R. et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci. Transl. Med. 11, eaav1648 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Muller, F. et al. CD19 CAR T-cell therapy in autoimmune disease — a case series with follow-up. N. Engl. J. Med. 390, 687–700 (2024).

Article  PubMed  Google Scholar 

Wilkinson, M. G. L. & Rosser, E. C. B cells as a therapeutic target in paediatric rheumatic disease. Front. Immunol. 10, 214 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Liu, T. et al. Spatial transcriptomics identifies cellular and molecular characteristics of scleroderma skin lesions: pilot study in juvenile scleroderma. Int. J. Mol. Sci. 25, 9182 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Torok, K. S. Updates in systemic sclerosis treatment and applicability to pediatric scleroderma. Rheum. Dis. Clin. North. Am. 47, 757–780 (2021).

Article  PubMed  Google Scholar 

Bloom, J. L. & Wu, E. Y. Update on antineutrophil cytoplasmic autoantibody vasculitis in children. Curr. Opin. Rheumatol. 36, 336–343 (2024).

Article  CAS  PubMed  Google Scholar 

Mahmoud, I. et al. Efficacy and safety of rituximab in the management of pediatric systemic lupus erythematosus: a systematic review. J. Pediatr. 187, 213–219.e2 (2017).

Article  CAS  PubMed  Google Scholar 

Balevic, S. J. et al. Extrapolation of adult efficacy data to pediatric systemic lupus erythematosus: evaluating similarities in exposure-response. J. Clin. Pharmacol. 63, 105–118 (2023).

Article  CAS  PubMed  Google Scholar 

Sherman, M. A. et al. Treatment escalation patterns to start biologics in refractory moderate juvenile dermatomyositis among members of the Childhood Arthritis and Rheumatology Research Alliance. Pediatr. Rheumatol. Online J. 21, 3 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Oddis, C. V. et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 65, 314–324 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aggarwal, R. et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol. 66, 740–749 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gagne, S. J. et al. Comparing rituximab and cyclophosphamide in induction therapy for childhood-onset anti-neutrophil cytoplasmic antibody-associated vasculitis: an ARChiVe registry cohort study. Arthritis Care Res. 77, 504–512 (2025).

Article  CAS  Google Scholar 

Jamois, C. et al. Rituximab pediatric drug development: pharmacokinetic and pharmacodynamic modeling to inform regulatory approval for rituximab treatment in patients with granulomatosis with polyangiitis or microscopic polyangiitis. Clin. Transl. Sci. 15, 2172–2183 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Md Yusof, M. Y. et al. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Ann. Rheum. Dis. 76, 1829–1836 (2017).

Article  PubMed  Google Scholar 

Wobma, H., Chang, J. C. & Prockop, S. E. Releasing our model T — chimeric antigen receptor (CAR) T-cells for autoimmune indications. Curr. Opin. Rheumatol. 37, 128–135 (2025).

Article  CAS  PubMed  Google Scholar 

Tur, C. et al. CD19-CAR T-cell therapy induces deep tissue depletion of B cells. Ann. Rheum. Dis. 84, 106–114 (2025).

Article  CAS  PubMed  Google Scholar 

Krickau, T. et al. CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis. Lancet 403, 1627–1630 (2024).

Article  CAS  PubMed  Google Scholar 

He, X. et al. Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells. Autoimmun. Rev. 24, 103692 (2025).

Article  CAS  PubMed  Google Scholar 

Nicolai, R. et al. Autologous CD19-targeting CAR T cells in a patient with refractory juvenile dermatomyositis. Arthritis Rheumatol. 76, 1560–1565 (2024).

CAS  PubMed  Google Scholar 

Schett, G. et al. Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat. Rev. Rheumatol. 20, 531–544 (2024).

Article  PubMed  Google Scholar 

Chung, J. B., Brudno, J. N., Borie, D. & Kochenderfer, J. N. Chimeric antigen receptor T cell therapy for autoimmune disease. Nat. Rev. Immunol. 24, 830–845 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stojkic, I. et al. CAR T cell therapy for refractory pediatric systemic lupus erythematosus: a new era of hope? Pediatr. Rheumatol. Online J. 22, 72 (2024).